RESUMEN
Atherosclerosis and the expression of monocyte chemoattractant protein-1 (MCP-1) were quantified in low density lipoprotein receptor knockout (LDLR KO) mice fed 1.25% cholesterol (study #1) or 0.2% cholesterol (study #2). In study #1 plasma total cholesterols leveled-off at 1800 mg/dl whereas plasma triglycerides remained low. In en face specimens of the aortic root and arch, intimal foam cells plus extracellular lipid particles accumulated and by 8 weeks the fatty streak surface area had rapidly expanded at both sites. In study #2, total cholesterols averaged 400 mg/dl and fatty streaks were 2-3-fold smaller compared to those in study #1. In study #3, LDLR KO mice were fed chow or 1.25% cholesterol, and immunostaining demonstrated a few Mac-2-positive intimal macrophages in mice fed chow, and during the first 10 weeks of hypercholesterolemia the number of intimal macrophages increased continuously. In chow-fed mice (0 weeks) there was little MCP-1 in the aorta. After 2 days of hypercholesterolemia intimal macrophages stained for MCP-1, and during the next 10 weeks recently recruited arterial macrophages also expressed MCP-1. Macrophage accumulation was highly correlated with MCP-1 expression. In study #4, feeding LDLR KO mice 1.25% cholesterol for 6 months produced atherosclerotic plaques at both sites and they contained a fibrous cap of smooth muscle cells, macrophage-foam cells, connective tissue and cholesterol crystals. In summary, LDLR KO mice fed cholesterol develop fatty streaks that transform into fibrous plaques. Hypercholesterolemia rapidly triggers MCP-1 expression in resident intimal macrophages, which is followed by the accumulation of more macrophages that also express MCP-1, suggesting that this chemokine may both initiate and amplify monocyte recruitment to the artery wall during early atherogenesis.
Asunto(s)
Aorta/metabolismo , Arteriosclerosis/metabolismo , Arteriosclerosis/patología , Quimiocina CCL2/análisis , Macrófagos/patología , Animales , Aorta/patología , Colesterol en la Dieta/administración & dosificación , Modelos Animales de Enfermedad , Femenino , Inmunohistoquímica , Lipoproteínas/sangre , Ratones , Ratones Noqueados , Probabilidad , Receptores de LDL/metabolismo , Valores de Referencia , Sensibilidad y Especificidad , Programas Informáticos , Estadísticas no Paramétricas , Túnica Íntima/metabolismo , Túnica Íntima/patologíaRESUMEN
Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase and angiotensin-converting enzyme (ACE) reduce experimental atherosclerosis by different mechanisms. To determine whether dual-drug therapy additively retards the progression of early lesions, control hyperlipidemic hamsters were compared with those treated with pravastatin, captopril, and pravastatin plus captopril. After 8 weeks of treatment, pravastatin (34 mg/kg/day) reduced plasma total cholesterol and triglycerides by 41 and 84%, respectively, whereas captopril (100 mg/kg/day) reduced normal blood pressure by 21%. The combination of pravastatin and captopril (33 and 100 mg/kg/day) decreased plasma total cholesterol and triglycerides by 44 and 84%, and blood pressure was decreased by 14%. In the aortic arch, pravastatin reduced macrophage-foam cell size and fatty streak area by 21 and 31%, respectively, whereas captopril decreased macrophage-foam cell number and fatty streak area by 34 and 35%. Pravastatin plus captopril decreased macrophage-foam cell number, foam cell size, and fatty streak area by 38, 24, and 67%. ACE inhibitors were previously reported to retard atherosclerosis without affecting blood pressure, suggesting that these agents acted on the artery wall. Therefore the expression of arterial ACE was determined in normal and atherosclerotic hamster aortas. ACE messenger RNA (mRNA) and protein were detected in endothelial cells, intimal macrophage-foam cells and medial smooth-muscle cells of atherosclerotic arteries indicating an upregulation of ACE expression with hyperlipidemia and atherosclerosis. In conclusion, dual-therapy with pravastatin and captopril produced an additive reduction in fatty streak area compared with either drug alone and suggested that atherogenesis can be retarded beyond the level achieved with monotherapy. The presence of ACE in endothelial cells and intimal macrophage-foam cells provides cellular targets for captopril to directly modify the formation of early atherosclerotic lesions.
Asunto(s)
Inhibidores de la Enzima Convertidora de Angiotensina/uso terapéutico , Anticolesterolemiantes/uso terapéutico , Arteriosclerosis/tratamiento farmacológico , Arteriosclerosis/enzimología , Captopril/uso terapéutico , Peptidil-Dipeptidasa A/metabolismo , Pravastatina/uso terapéutico , Animales , Arteriosclerosis/patología , Presión Sanguínea/efectos de los fármacos , Colesterol/sangre , Cricetinae , Inmunohistoquímica , Lípidos/sangre , Lipoproteínas/biosíntesis , Lipoproteínas/sangre , Masculino , Mesocricetus , ARN Mensajero/biosíntesisRESUMEN
Recent studies suggest that endothelin and its receptors may be involved in atherogenesis. To test this hypothesis, cholesterol-fed hamsters were treated with a selective endothelin subtype A (ETA) receptor antagonist BMS-182874. Characterization of hamster atherosclerotic plaques indicated that they contained a fibrous cap of smooth muscle cells, large macrophage-foam cells, and epitopes of oxidized low density lipoprotein. Messenger RNA for both ETA and ETB receptors was detected in aortic endothelial cells, in medial smooth muscle cells, and in macrophage-foam cells and smooth muscle cells of the fibro-fatty plaques. BMS-182874 inhibited the endothelin-1-induced pressor response whereas the depressor effect was unaltered, suggesting that vascular ETA receptors were selectively blocked in vivo. In hyperlipidemic hamsters, BMS-182874 decreased the area of the fatty streak by reducing the number and size of macrophage-foam cells. The results indicated that ETA receptors and thus endothelin promoted the early inflammatory phase of atherosclerosis.
Asunto(s)
Arteriosclerosis/inmunología , Arteriosclerosis/prevención & control , Compuestos de Dansilo/farmacología , Antagonistas de los Receptores de Endotelina , Animales , Aorta/efectos de los fármacos , Aorta/patología , Arteriosclerosis/etiología , Presión Sanguínea/efectos de los fármacos , Colesterol en la Dieta , Cricetinae , Cricetulus , Lípidos/sangre , Masculino , Mesocricetus , ARN Mensajero/metabolismo , Receptor de Endotelina ARESUMEN
We determined whether inhibiting angiotensin-converting enzyme (ACE) with fosinopril or captopril induced the regression of atherosclerosis in hamsters. A pressor experiment demonstrated that 100 mg/kg fosinopril or captopril almost completely inhibited ACE activity in vivo. Another study established that feeding hamsters 0.05% cholesterol and 10% coconut oil resulted in rapid and progressive accumulation of oil red O-stained macrophage-foam cells in the aortic arch. In the regression study, three groups of hamsters were fed the same atherogenic diet for 4 weeks to induce fatty lesions in the arch. After 4 weeks, plasma lipids, blood pressure (BP), and atherosclerosis were quantified in control hamsters. Beginning at 4 weeks, the two remaining groups of hamsters were treated with 100 mg/kg/day fosinopril or 100 mg/kg/day captopril for 6 more weeks while receiving the atherogenic diet. After 6-week treatment, plasma lipids, BP, and atherosclerosis were quantified in the two treated groups (i.e., study week 10), and they were compared with the 4-week controls. As compared with that in controls, fosinopril decreased plasma low density lipoprotein (LDL) and very low density lipoprotein (VLDL) cholesterols by approximately 69%. High density lipoprotein (HDL) cholesterol decreased by 16% and total triglycerides decreased by 56% as compared with that of controls. Captopril did not alter LDL plus VLDL cholesterols or total triglycerides, but HDL cholesterol decreased by 24% as compared with that of the control group. As compared with that of control hamsters, mean arterial BP (MAP) decreased by 9% with captopril treatment, and heart rate (HR) was decreased by both fosinopril and captopril.(ABSTRACT TRUNCATED AT 250 WORDS)
Asunto(s)
Arteriosclerosis/tratamiento farmacológico , Captopril/uso terapéutico , Fosinopril/uso terapéutico , Hiperlipidemias/complicaciones , Análisis de Varianza , Animales , Aorta Torácica/efectos de los fármacos , Aorta Torácica/patología , Arteriosclerosis/complicaciones , Presión Sanguínea/efectos de los fármacos , Presión Sanguínea/fisiología , Captopril/farmacología , Recuento de Células/efectos de los fármacos , Colesterol en la Dieta/administración & dosificación , HDL-Colesterol/sangre , LDL-Colesterol/sangre , VLDL-Colesterol/sangre , Cricetinae , Dieta Aterogénica , Modelos Animales de Enfermedad , Células Espumosas/efectos de los fármacos , Fosinopril/farmacología , Frecuencia Cardíaca/efectos de los fármacos , Frecuencia Cardíaca/fisiología , Hiperlipidemias/tratamiento farmacológico , Procesamiento de Imagen Asistido por Computador , Macrófagos/efectos de los fármacos , MasculinoRESUMEN
As part of an ongoing biochemical study in nutrition we examined blood profiles, serum chemistry, lymphocyte transformation and lymphoid pathology in cats fed a diet containing 5% cystine with and without taurine. Automated blood counts of whole blood samples showed a decrease in red blood cell counts accompanied by a significant decrease in hemoglobin and hematocrit in cats fed 5% cystine in the absence of taurine compared to cats fed 0.05% taurine (control). A significant increase was noted in serum cholesterol in cats fed cystine and cystine/taurine compared to cats fed control diets. There were no significant differences in lymphocyte transformation using leukocytes isolated from the spleen and blood with the mitogens, phytohemagglutinin and pokeweed. However, lymphocyte transformation of both spleen and blood without mitogen from the excess cystine group were significantly higher than leukocytes from the 0.05% taurine group (control). Pathological examination of regional lymph nodes, livers, and spleens showed histological abnormalities in cats fed the excess cystine diet. These results indicate that there are alterations in the immune system of cats fed a diet containing 5% cystine with and without dietary taurine.